GLP-1 receptor agonists bind to GLP-1 receptors and activate them, causing physiological processes in the body to be stimulated. GLP-1 receptor agonists enhance insulin secretion by interacting with GLP-1 receptors in pancreatic beta cells. As a result, GLP-1 Receptor Agonist can be utilised to treat diabetes. Inhibition of glucagon synthesis from pancreatic alpha cells in the case of high blood sugar levels is one of the advantages of employing GLP-1 receptor agonist for the treatment of type-2 diabetes. Glucagon is a hormone that stimulates the liver to convert glycogen into glucose, thus increasing the concentration of glucose in the blood. Furthermore, GLP-1 receptor agonists can increase pancreatic beta-cell proliferation while decreasing apoptosis (cell death).
